Scynexis Inc Dossier
Qualitative Analysis
Business overview
SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases and difficult-to-treat or drug-resistant fungal infections. The company's proprietary fungerp platform has yielded ibrexafungerp (formerly SCY-078), a novel, broad-spectrum, structurally distinct triterpenoid glucan synthase inhibitor. Ibrexafungerp was approved by the FDA under the brand name BREXAFEMME for vulvovaginal candidiasis (VVC) and recurrent VVC (rVVC) in 2021 and 2022, respectively, and was subsequently licensed to GlaxoSmithKline (GSK) in May 2023. SCYNEXIS is currently focusing its internal development efforts on its second-generation fungerp, SCY-247, which is in Phase 1 clinical trials for systemic and invasive fungal infections, and has recently expanded its pipeline into rare kidney diseases through the acquisition of SCY-770 (formerly PXL-770), a direct AMPK activator for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing SCY-770 (formerly PXL-770), a novel, highly selective, direct oral AMPK activator, as a disease-modifying therapy for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Expected impact: Establishes a clinical-stage pipeline in severe rare kidney diseases, targeting a multi-billion-dollar market with high unmet need.
Developing SCY-247, a second-generation fungerp (triterpenoid antifungal), for life-threatening systemic fungal infections, including the initiation of an expanded access program.
Expected impact: Provides a broad-spectrum treatment option against multi-drug resistant fungal pathogens like Candida auris.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of global rights to PXL-770 (renamed SCY-770) and the direct AMPK activator platform to pivot SCYNEXIS's strategic focus toward severe rare diseases.
Financial impact: Incurred an $8.0 million upfront payment recognized as in-process research and development (IPR&D) expense in Q1 2026, with up to $188.0 million in future milestone obligations.
Strategic Partnerships
Out-licensing of BREXAFEMME (ibrexafungerp) to leverage GSK's global commercial infrastructure, allowing SCYNEXIS to focus resources on its rare disease pipeline.
Terms: $90.0 million upfront payment received at closing, a $25.0 million development milestone achieved in June 2023, a $24.8 million resolution payment in Q4 2025, and eligibility for up to $146.0 million in annual net sales milestones plus low-to-mid-single-digit royalties.